Patient Research
Sign in
All studies
RecruitingPHASE1INTERVENTIONAL

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

At a glance

Status
Recruiting
Phase
PHASE1
Sponsor
Alnylam Pharmaceuticals
Enrolment target
66
Start
14 Oct 2024
Estimated completion
05 Jul 2028
Huntington's Disease

What is this study about?

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.

Who may be eligible?

Age 25 Years to 70 Years · Sex: ALL

Locations (19)

  • Clinical Trial Site
    Edmonton, Canada· Recruiting
  • Clinical Trial Site
    Montreal, Canada· Recruiting
  • Clinical Trial Site
    Ottawa, Canada· Recruiting
  • Clinical Trial Site
    Vancouver, Canada· Recruiting
  • Clinical Trial Site
    Berlin, Germany· Recruiting
  • Clinical Trial Site
    Bochum, Germany· Recruiting
  • Clinical Trial Site
    Bonn, Germany· Recruiting
  • Clinical Trial Site
    Dresden, Germany· Recruiting
  • Clinical Trial Site
    Münster, Germany· Recruiting
  • Clinical Trial Site
    Taufkirchen, Germany· Recruiting
  • Clinical Trial Site
    Ulm, Germany· Recruiting
  • Clinical Trial Site
    Birmingham, United Kingdom· Recruiting

+7 more sites — see the official record for the full list.

How to find out more

Alnylam Clinical Trial Information Line

clinicaltrials@alnylam.com 1-877-ALNYLAM Official trial record

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Study to Evaluate ALN-HTT02 in Adult Patients With Hunting…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.